

India Equity Research | BFSI - NBFCs August 13, 2021

Result Update

Refer to important disclosures at the end of this report

Healthy performance, asset quality improves

- PFC reported healthy trends in profitability, with PAT of Rs22.7bn (+33.8% yoy, -2.3%) gog), driven by improvement in margins (~381bps) and credit costs (~49bps vs. ~86bps last quarter). However, disbursements remained weak at Rs113.3bn (-45.4% yoy, -18.2% qoq), mainly due to weak demand across segments.
- Asset-quality trends were encouraging, as out of the total Stage-3 assets of Rs211.5bn for 26 projects, 16 projects worth Rs158.2bn are already admitted under the NCLT with ~69% provision coverage, while 10 projects worth Rs53.3bn with 54% coverage are being pursued outside the NCLT. Overall coverage improved to ~65% from ~63% last guarter.
- Yields are re-prized at lower rates from Apr'21 to improve competitiveness among lenders. Hedging of ~86% of forex loans (maturing up to 5 years) also provides comfort over volatile forex losses. Aatmanirbhar plans for SEB may support near-term disbursements; however, finding new growth avenues - amid weak thermal power additions - is a necessity.
- We continue to like the company based on improving asset-quality trends and an attractive risk-reward. Maintain Buy and roll forward to Sept'22E with a revised TP of Rs220 (Rs215 earlier), corresponding to ~1x P/Adj. Sept'23E book. We are increasing the dividend payout estimate to ~45% by FY24E, based on revised guidelines from the RBI.

Disbursement momentum remains weak; new avenues of growth necessary: Disbursements during the quarter remained weak at Rs113.3bn (-45.4% yoy, -18.2% qoq), mainly due to weak demand across segments. Total AUM remained flat sequentially at Rs3.7th on lower disbursements. In our opinion, in the absence of any major capex plans in the thermal power segment, the company needs to find new avenues of growth to maintain existing leverage.

Asset-quality trends continue to see improvement; gradual resolution of legacy portfolio expected: On asset quality, PFC has witnessed an improvement in Gross Stage-3 assets to ~5.72% from ~7.5% last year, while Net Stage 3 has improved to 2% from 3.41% last year. Asset-quality trends remained encouraging, as out of the total Stage-3 assets of Rs211.5bn for 26 projects, 16 projects worth Rs158.2bn are already admitted under the NCLT with ~69% provision coverage, while 10 projects worth Rs53.3bn with 54% coverage are being pursued outside the NCLT. Overall coverage improved to ~65% from ~63% last quarter.

Outlook and valuation: We are valuing PFC using sum-of-the-parts (SOTP) - standalone PFC is valued by discounting profits in excess of RoE, and we add the value of 52.6% stake in REC at current market cap, after applying a 30% hold-co discount. We continue to like the company based on improving asset-quality trends and attractive risk-reward. We maintain our Buy rating and OW stance in EAP and roll forward to Sept'22E with a revised TP of Rs220, corresponding to ~1x P/Adj. Sept'23E book. We are increasing the dividend payout estimate to ~45% by FY24E, based on revised guidelines from the RBI.

Please see our sector model portfolio (Emkay Alpha Portfolio): BFSI-NBFCs (Page 7)

Financial Snapshot (Standalone)

(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Net income	115,179	145,721	142,939	136,769	136,026
Net profit	56,551	84,440	88,301	82,662	83,498
EPS (Rs)	21.4	32.0	33.4	31.3	31.6
ABV (Rs)	133.8	176.5	199.6	217.6	234.2
RoA (%)	1.6	2.2	2.2	2.0	2.1
RoE (%)	12.8	17.3	16.0	13.6	12.8
PE (x)	6.1	4.1	3.9	4.1	4.1
P/ABV	1.0	0.7	0.6	0.6	0.6

Source: Company, Emkay Research



СМР	Target Price
Rs 130 as of (August 13, 2021)	Rs 220 (▲) 12 months
Rating	Upside
BUY (∎)	69.7 %

Change in Estimates

Change in Es	sumat	es		
EPS Chg FY2	22E/F1	(23E (%	%) (*	1.4)/(9.3)
Target Price of	change	e (%)		2.3
Target Period	(Mon	ths)		12
Previous Rec	0			BUY
Emkay vs Co	onsen	sus		
	EPS E	stimat	es	
		F	Y22E	FY23E
Emkay			33.4	31.3
Consensus			34.2	39.7
Mean Conser	isus T	P (12N	1)	Rs 178
Stock Details	;			
Bloomberg Co	ode			POWF IN
Face Value (F	₹s)			10
Shares outsta	inding	(mn)		2,640
52 Week H/L				141 / 82
M Cap (Rs br	/USD	bn)	3	42 / 4.61
Daily Avg Vol	ume (ı	nos.)	7	7,537,279
Daily Avg Tur	nover	(US\$ r	nn)	12.7
Shareholding	g Patt	ern Ju	n '21	
Promoters				56.0%
Flls				17.4%
DIIs				19.4%
Public and Ot	hers			7.3%
Price Perform	nance			
(%)	1M	3M	6M	12M
Absolute	5	12	3	
Rel. to Nifty	1	1	(5)	(2)
			(0)	(2)
Relative pric	e cha	rt		
¹⁵⁰ Rs				% 20
136 -		1		- 12
122 -	M.,			W 4
108 - 10	[] proven	/~ h		VM ₄
N TN	<i>,</i>	H	W.	· W.
94 -				12
80		οh-21 Δn	r-21 lun	-20
Power Finar				Rel to Nifty (RHS)
Source: Bloom				
This report is sol				
following person	s) are r	esnonsit	ole for th	ne

following person(s) are responsible for the production of the recommendation:

Jignesh Shial

jignesh.shial@emkayglobal.com +91 22 6624 2468

Anand Dama

anand.dama@emkayglobal.com +91 22 6624 2480

Aman Jain

aman.jain@emkayglobal.com +91 22 6612 1285

Shrishti Jagati

shrishti.jagati@emkayglobal.com +91 22 6624 2485

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Story in Charts




Exhibit 1: AUM growth stands at ~4.6% yoy

Source: Company, Emkay Research

Exhibit 3: NIMs improved on lower cost of funds






Exhibit 2: Decline in disbursements but supported by Atmanirbhar sanctions



Source: Company, Emkay Research


Exhibit 4: Asset quality improves while coverage expands




Source: Company, Emkay Research


Source: Company, Emkay Research

Exhibit 5: Dividend payout ratio to increase after revised guidelines from RBI



Source: Company, Emkay Research





Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 7: Quarterly financials

Rs mn	1QFY21	2QFY21	3QFY21	4QFY21	1QFY22	YoY (%)	QoQ (%)	FY21	FY22E	YoY (%)
Net Interest Income	30,728	33,645	34,421	30,719	35,246	14.7%	14.7%	129,513	138,940	7.3%
Other Income	254	380	7,586	7,988	622	144.6%	-92.2%	16,208	3,999	-75.3%
Total Income	30,982	34,025	42,007	38,706	35,867	15.8%	-7.3%	145,721	142,939	-1.9%
Operating Expenses	6,189	-462	119	2,838	3,767	-39.1%	32.7%	8,684	10,754	23.8%
Operating Profit	24,794	34,487	41,888	35,868	32,101	29.5%	-10.5%	137,037	132,185	-3.5%
Provisions	3,530	9,532	13,972	7,930	4,505	27.6%	-43.2%	34,964	18,978	-45.7%
CoR (%)	0.40%	1.05%	1.52%	0.86%	0.49%			1.00%	0.50%	
PBT	21,264	24,956	27,916	27,938	27,595	29.8%	-1.2%	102,073	113,207	10.9%
Tax	4,268	4,105	4,588	4,672	4,860	13.9%	4.0%	17,633	24,905	41.2%
Tax rate (%)	20.1%	16.4%	16.4%	16.7%	17.6%			17.3%	22.0%	
PAT	16,996	20,851	23,328	23,266	22,736	33.8%	-2.3%	84,440	88,301	4.6%
Disbursements	172,710	288,340	138,470	283,500	113,320	-45.4%	-18.2%	883,020	697,793	-21.0%
Total AUM	3,535,950	3,711,580	3,650,310	3,707,720	3,699,830	7.3%	1.4%	3,707,720	3,883,601	4.7%

Source: Company, Emkay Research

Exhibit 8: Changes in earnings estimates

Y/e Mar (Rs mn)		FY22E			FY23E			FY24E	
	Earlier	Revised	% change	Earlier	Revised	% change	Earlier	Revised	% change
Net interest income	148,070	142,678	-3.6%	147,360	136,456	-7.4%	148,066	135,651	-8.4%
PPOP	140,295	132,185	-5.8%	139,466	126,716	-9.1%	140,128	125,730	-10.3%
PAT	89,587	88,301	-1.4%	91,180	82,662	-9.3%	91,697	83,498	-8.9%
EPS (Rs)	33.9	33.4	-1.4%	34.5	31.3	-9.3%	34.7	31.6	-8.9%
BV (Rs)	222	220	-0.9%	246	239	-3.0%	271	256	-5.3%

Source: Company, Emkay Research

Exhibit 9: Key assumptions

(%)	FY21	FY22E	FY23E	FY24E
Loan growth	7.8%	4.6%	-0.9%	-1.7%
Borrowing growth	7.3%	3.9%	-3.1%	-3.9%
Yield on average loans	10.7%	10.0%	9.5%	9.3%
Cost of average int. liabilities	7.2%	6.8%	6.6%	6.5%

Source: Emkay Research

Exhibit 10: SOTP valuation

Particulars	Contribution (%)	Value per share (Rs)	Rationale
Core business	81.8%	180	ERoE
Value of Subsidiaries - REC Limited	18.2%	40	M Cap basis
Target Price		220	

Source: Emkay Research

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Net interest income	115,097	145,504	142,678	136,456	135,651
Other income	82	217	260	312	375
Fee income	0	0	0	0	0
Net income	115,179	145,721	142,939	136,769	136,026
Operating expenses	23,341	8,684	10,754	10,052	10,296
Pre provision profit	91,838	137,037	132,185	126,716	125,730
PPP excl treasury	91,838	137,037	132,185	126,716	125,730
Provisions	9,912	34,964	18,978	15,462	13,351
Profit before tax	81,925	102,073	113,207	111,254	112,379
Тах	25,374	17,633	24,905	28,592	28,881
Tax rate	31	17	22	26	26
Profit after tax	56,551	84,440	88,301	82,662	83,498

Balance Sheet

Y/E Year End (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity	26,401	26,401	26,401	26,401	26,401
Reserves	425,241	497,530	554,926	604,523	650,447
Net worth	451,641	523,931	581,327	630,924	676,848
Deposits	0	0	0	0	0
Borrowings	3,108,746	3,334,534	3,465,726	3,358,906	3,228,132
Total liabilities	3,617,873	3,920,841	4,115,511	4,064,979	3,987,488
Cash and bank	1,990	47,622	58,597	43,788	31,708
Investments	164,733	159,735	173,286	167,945	161,407
Loans	3,341,126	3,601,248	3,767,093	3,732,118	3,668,332
Others	109,710	111,864	116,125	120,678	125,546
Total assets	3,617,873	3,920,841	4,115,511	4,064,979	3,987,488

Key Ratios (%)

Y/E Year End	FY20	FY21	FY22E	FY23E	FY24E
NIM	3.5	4.1	3.8	3.5	3.6
Non-II/avg assets	0.0	0.0	0.0	0.0	0.0
Fee income/avg assets	0.0	0.0	0.0	0.0	0.0
Opex/avg assets	0.0	0.0	0.0	0.0	0.0
Provisions/avg assets	0.0	0.0	0.0	0.0	0.0
PBT/avg assets	0.0	0.0	0.0	0.0	0.0
Tax/avg assets	0.0	0.0	0.0	0.0	0.0
RoA	1.6	2.2	2.2	2.0	2.1
RoAE	12.8	17.3	16.0	13.6	12.8
GNPA (%)	7.7	5.4	5.2	5.4	5.6
NNPA (%)	3.6	2.0	1.8	1.8	2.0
Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	21.4	32.0	33.4	31.3	31.6
BVPS	171.1	198.4	220.2	239.0	256.4
ABVPS	133.8	176.5	199.6	217.6	234.2
DPS	9.5	10.0	11.7	12.5	14.2
Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	6.1	4.1	3.9	4.1	4.1
P/BV	1.0	0.7	0.6	0.6	0.6
P/ABV	1.0	0.7	0.6	0.6	0.6
P/PPOP	0.0	0.0	0.0	0.0	0.0
Dividend Yield (%)	7.3	7.7	9.0	9.7	11.0

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
NII	17.7	26.4	(1.9)	(4.4)	(0.6)
PPOP	2.7	49.2	(3.5)	(4.1)	(0.8)
PAT	(18.7)	49.3	4.6	(6.4)	1.0
Loans	10.2	7.8	4.6	(0.9)	(1.7)

Quarterly (Rs mn)	Q1FY21	Q2FY21	Q3FY21	Q4FY21	Q1FY22
NII	30,728	33,645	34,421	30,719	35,246
NIM(%)	3.5	3.7	3.7	3.3	3.8
PPOP	24,794	34,487	41,888	35,868	32,101
PAT	-	-	-	-	-
	6.44	7.90	8.84	8.81	8.61
EPS (Rs)	0.44	7.90	0.04	0.01	0.01
EPS (RS) Source: Company, Emkay Research	0.44	7.90	0.04	0.01	0.01
	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21
Source: Company, Emkay Research					
Source: Company, Emkay Research Shareholding Pattern (%)	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21
Source: Company, Emkay Research Shareholding Pattern (%) Promoters	Jun-20 56.0	Sep-20 56.0	Dec-20 56.0	Mar-21 56.0	Jun-21 56.0

Source: Capitaline

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY TABLE

Date	Closing Price	ТР	Period (months)	Rating	Analyst	
16-Jun-21	129	215	12m	Buy	Jignesh Shial	
19-Feb-21	124	210	12m	Buy	Jignesh Shial	
11-Feb-21	128	210	12m	Buy	Jignesh Shial	
14-Jan-21	121	210	12m	Buy	Jignesh Shial	

RECOMMENDATION HISTORY CHART



Source: Company, Emkay Research

Source: Bloomberg, Company, Emkay Research

Emkay Alpha Portfolio – BFSI-NBFCs

EAP sector portfolio

-

Analyst: Jignesh Shial

Contact Details

jignesh.shial@emkayglobal.com +91 22 6624 2468

Sector

NBFCs/AFCs

Analyst bio

Jignesh Shial is a CA and has total 13 years of research experience. His team currently covers 11 NBFCs/AFCs.

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
BFSI-NBFCs	7.79	7.79	0%	0	100.00
Bajaj Finance	1.77	1.77	0%	0	22.67
Cholamandalam Investment	0.22	0.22	0%	0	2.78
Edelweiss Financial Services	0.00	0.00	NA	0	0.00
HDFC	5.17	5.20	1%	3	66.68
L&T Finance Holdings	0.07	0.07	0%	0	0.93
LIC Housing Finance	0.13	0.13	0%	0	1.66
Mahindra Finance	0.10	0.00	-100%	-10	0.00
Nippon Life India Asset Management	0.06	0.06	0%	0	0.78
Ponawalla Finco*	0.00	0.04	NA	4	0.48
Shriram City Union Finance	0.00	0.03	NA	3	0.40
Shriram Transport Finance	0.28	0.28	0%	0	3.61
Cash	0.00	0.00	NA	0	0.00

Source: Emkay Research

* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

Sector portfolio NAV

	Base					Latest
	1-Apr-19	13-Aug-20	11-Feb-21	12-May-21	13-Jul-21	12-Aug-21
EAP - BFSI-NBFCs	100.0	93.1	146.2	133.2	143.1	146.9
BSE200 Neutral Weighted Portfolio (ETF)	100.0	87.8	137.5	125.0	134.3	137.7


*Performance measurement base date 1st April 2019 Source: Emkay Research

Price Performance (%)

	1m	3m	6m	12m
EAP - BFSI-NBFCs	2.7%	10.3%	0.5%	57.8%
BSE200 Neutral Weighted Portfolio (ETF)	2.6%	10.2%	0.2%	56.9%

Source: Emkay Research

NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

Expected Return within the next 12-18 months.	
Over 15%	
Between -5% to 15%	
Below -5%	

Completed Date: 13 Aug 2021 19:02:09 (SGT) Dissemination Date: 13 Aug 2021 19:03:09 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of August 13, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of August 13, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the August 13, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the August 13, 2021

RESTRICTIONS ON I	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com